Displaying drugs 15426 - 15450 of 15569 in total
Mosapramine
Experimental
Vapitadine
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and …
Roxarsone
Roxarsone is an organoarsenic molecule added to poultry feed. The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent the growth of coccidian parasites. The drug is also approved in the United States for use in pigs.
Vet approved
Matched Description: … The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent …
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
Carmegliptin
Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Investigational
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
Ragaglitazar
Investigational
2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID
Experimental
PF-00446687
PF-00446687 has been investigated for the treatment of Erectile Dysfunction.
Investigational
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.
Experimental
Matched Description: … (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and …
3-amino-5-phenylpentane
3-amino-5-phenylpentane is a solid. This compound belongs to the phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K and cathepsin L2.
Experimental
Matched Description: … substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K and …
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Description: … blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and …
CY-1503
CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl unit. It was investigated in cardiopulmonary bypass during surgical repair of congenital heart lesions.
Investigational
Matched Description: … as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and …
Carbon black
Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment with demonstrated adverse effects on pulmonary function. Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue and has been linked to carcinogenicity.[A263406, A263411, A263416]
Investigational
Matched Description: … inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and …
4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID
Experimental
CHF 4227
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
Displaying drugs 15426 - 15450 of 15569 in total